Dear Authors,
If you believe that your paper was mistakenly rejected by other leading journals and you do not agree with final decision, the editors of Reports of Practical Oncology and Radiotherapy offer new fast track review. You may submit your manuscript to Reports of Practical Oncology and Radiotherapy together with all prior peer-reviews obtained from the other journal and your rebuttal letter. We guarantee review based decision within 72 hours from the time we will receive your manuscript.

Fast track submission process: Please submit the manuscript with all reviews and rebuttal letter by email to Dr. Michal Masternak (michal.masternak@ucf.edu) for fast review processing. To assure immediate attention the email title must to include: RPOR-fast track- Last Name First Name (of corresponding author).

Volume 18, Number 5, 2013

Tamoxifen in breast cancer ipse dixit in uterine malignant mixed Müllerian tumor and sarcoma—A report of 8 cases and review of the literature

Ana Luisa Cardoso Vasconcelos, Beatriz Nunes, Catarina Duarte, Vera Mendonca, Joana Ribeiro, Marília Jorge, Isabel Monteiro Grillo

Summary:

Aim: Report the outcome of 8 patients (pts) with breast cancer (BC) treated with Tamoxifen
(TAM) that developed malignant mixed Müllerian tumor (MMMT) and rare uterine sarcoma
(RUS).
Patients and methods: Retrospective study based on data collected from the department medical records between April 1999 and September 2010 among 583 pts with endometrial cancer, 36 pts with MMMT and RUS histopathology. Among them, 8 pts underwent TAM between 4
and 10 years due to a previous diagnosis of BC; all pts were post-menopausal with regular
gynecological surveillance; 6 pts (75%) with abnormal uterine bleeding. The diagnosis of 6
pts (MMMT) and 2 pts (RUS) occurred at median interval of 8 years (range 4–12) after initial
BC treatment. Pts underwent surgical treatment and were staged as stage I (3pts), IIIA (3pts) and IIIC (2 pts) (FIGO 1988); followed by whole pelvis irradiation (50 Gy) and intracavitary HDR brachytherapy boost (24 Gy). Two pts underwent chemotherapy (CT). Overall and disease free survival was calculated by Kaplan Meier method.
Results: With a median follow-up of 47 months (range 17–130), 3 pts remain alive recurrencefree
of BC and RUS. Four pts died with distant metastasis within the first follow-up year, without BC. One pt died from non-related cancer cause. No evidence of local recurrence was found in the whole group of pts. At two years, DFS and OS were 40% and 80%, respectively.
Conclusion: As reported in the literature, TAM administration and causal effect on MMMT
and RUS in BC pts is still unknown. No reports about outcome from these specific pts were
found.

Signature: Rep Pract Oncol Radiother, 2013; 18(5) : 251-260


« back

 
INDEXED IN:

Indexed in: EMBASE®, the Excerpta Medica database, the Elsevier BIOBASE (Current Awareness in Biological Sciences) and in the Index Copernicus.

http://www.sciencedirect.com/science/journal/15071367/19/2